Details of the Drug

General Information of Drug (ID: DMQTFAO)

Drug Name
FLUORESCEIN
Synonyms Ful-Glo; Fluoreseptic; 41935-48-2; NSC5070
Indication
Disease Entry ICD 11 Status REF
Ocular disease 1F00.1Z Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
S01JA01: FLUORESCEIN
S01JA: Colouring agents
S01J: DIAGNOSTIC AGENTS
S01: OPHTHALMOLOGICALS
S: SENSORY ORGANS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 332.3
Logarithm of the Partition Coefficient (xlogp) 3.4
Rotatable Bond Count (rotbonds) 0
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption
The drug is rapidly distributed []
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [2]
Clearance
The renal clearance of drug is 1.75 mL/min/kg []
Half-life
The concentration or amount of drug in body reduced by one-half in 1.6 hours [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 23.1704 micromolar/kg/day [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.11% [3]
Vd
The volume of distribution (Vd) of drug is 0.5 L/kg []
Chemical Identifiers
Formula
C20H12O5
IUPAC Name
3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
Canonical SMILES
C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O
InChI
InChI=1S/C20H12O5/c21-11-5-7-15-17(9-11)24-18-10-12(22)6-8-16(18)20(15)14-4-2-1-3-13(14)19(23)25-20/h1-10,21-22H
InChIKey
GNBHRKFJIUUOQI-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
16850
ChEBI ID
CHEBI:31624
CAS Number
2321-07-5
UNII
TPY09G7XIR
DrugBank ID
DB00693
TTD ID
D06TJJ
VARIDT ID
DR00547

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mothers against decapentaplegic homolog 3 (SMAD3) TTHQZV7 SMAD3_HUMAN Inhibitor [5]
Solute carrier family 22 member 8 (SLC22A8) TTTQR47 S22A8_HUMAN Inhibitor [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [7]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [8]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [9]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5 In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6.
6 Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem. 2007 Aug 17;282(33):23841-53.
7 Hyaluronan export by the ABC transporter MRP5 and its modulation by intracellular cGMP. J Biol Chem. 2007 Jul 20;282(29):20999-1004.
8 Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C. Hepatology. 2010 Oct;52(4):1465-76.
9 Transport of fluorescein in MDCKII-MRP1 transfected cells and mrp1-knockout mice. Biochem Biophys Res Commun. 2001 Jun 22;284(4):863-9.
10 Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
11 Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs. J Pharmacol Exp Ther. 2018 Nov;367(2):322-334.
12 Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics. 2010 Mar 1;4:1-8.